Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for 177 Lu-DOTATATE therapy.

EJNMMI Phys · 2022 · PMC9110613 · PMID 35575946

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

The cross-dose contribution is significant for bone marrow [ 45 ] and may be significant for kidneys if its self-absorbed dose is low or if the tumor burden is high [ 46 ].

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.